首页|LncRNA OIP5-AS1通过调节miR-186-5p/KIF14信号轴来促进神经母细胞瘤的增殖

LncRNA OIP5-AS1通过调节miR-186-5p/KIF14信号轴来促进神经母细胞瘤的增殖

扫码查看
目的:神经母细胞瘤(NB)是儿童最常见的实体瘤。本研究旨在确定长链非编码 RNA(LncRNA)Opa相互作用蛋白 5 反义 RNA 1(OIP5-AS1)在 NB 中的作用及其可能的分子机制。方法:体外培养神经母细胞瘤细胞系SK-N-SH 和人神经母细胞 BE2C。通过定量实时聚合酶链式反应测定OIP5-AS1、miR-186-5p和驱动蛋白分子14(KIF14)的表达。使用 CCK-8 测定法、平板克隆形成法和EdU掺入法评估细胞增殖。蛋白质印迹法检测 KIF14 蛋白水平。通过在线数据库 Starbase3。0 预测靶基因,并通过双荧光素酶报告基因测定进行验证。结果:OIP5-AS1 在 SK-N-SH 细胞中的表达水平较BE2C细胞显著上调(1。88±0。14 vs 1。00±0。07),P<0。05。shOIP5-AS1 组下调OIP5-AS1 表达后,SK-N-SH细胞活力、克隆形成能力(111。33±15。57 个 vs 154。67±20。74 个 vs 149。33±17。01 个,P<0。05)和DNA合成能(EdU阳性细胞比例:35。09±8。02%vs 67。87±7。21%vs 63。33±7。17%,P<0。05)弱于 NC组和shCtrl组。经生物信息学预测和双荧光素酶报告基因验证,OIP5-AS1 与 miR-186-5p 以及 miR-186-5p与KIF14 3'-UTR 具有靶向调控作用。与 NC 组和 shCtrl 组相比,shOIP5-AS1 组 KIF14 mRNA相对表达量(0。41±0。09,P<0。05)和KIF14 蛋白表达(0。20±0。02,P<0。05)均下调。相反,shOIP5-AS1+miR-186-5p inhibitor组KIF14 mRNA相对表达量和KIF14 蛋白表达量分别为0。83±0。12 和 0。62±0。04,较shOIP5-AS1+miR-NC组升高。RNA结合蛋白免疫共沉淀结果也显示,与对照(IgG)相比,Ago2抗体可以富集OIP5-AS1 和miR-186-5p。与shOIP5-AS1+miR-NC组相比,shOIP5-AS1+miR-186-5p inhibitor组细胞活力和克隆形成能力(180。0±11。36 vs 136。0±14。53)显著增加(P<0。05)。在挽救性实验中,与shOIP5-AS1+miR-186-5p inhibitor+siNC 组相比,shOIP5-AS1+miR-186-5p inhibitor+siKIF14组细胞活力和克隆形成能力(139。33±8。96 vs 183。03±18。0,P<0。05)明显降低(P<0。05)。结论:SK-N-SH细胞中OIP5-AS1 表达水平显著上调,并且作为ceRNA竞争性地抑制miR186-5p,上调KIF14 表达,从而促进NB进展。
Effect of LncRNA OIP5-AS1 on Proliferation of Neuroblastoma by Regulating the miR-186-5p/KIF14 Signaling Axis
Objective:To determine the role of long non-coding RNA(LncRNA)Opa-interacting pro-tein 5 antisense RNA 1(OIP5-AS1)in NB and its potential molecular mechanisms.Methods:Neuroblastoma cell lines SK-N-SH and human neuroblastoma BE2C were cultured in vitro.The expression of OIP5-AS1,miR-186-5p,and kinesin family member 14(KIF14)was measured by quantitative real-time PCR.Cell proliferation was assessed using the CCK-8 assay,colony formation assay,and EdU incorporation assay.KIF14 protein levels were detected by Western blot.Target genes were predicted using the online database Starbase3.0 and verified by dual-luciferase reporter assay.Results:The expression level of OIP5-AS1 in SK-N-SH cells was significantly higher than that in BE2C cells(1.88±0.14 vs 1.00±0.07,P<0.05).After downregulating OIP5-AS1 expression in the shOIP5-AS1 group,SK-N-SH cell viability,colony formation a-bility(111.33±15.57 vs 154.67±20.74 vs 149.33±17.01,P<0.05),and DNA synthesis ability(EdU positive cell ratio:35.09±8.02%vs 67.87±7.21%vs 63.33±7.17%,P<0.05)were weaker than those in the NC group and shCtrl group.Bioinformatics prediction and dual-luciferase reporter assay confirmed the tar-geting regulation between OIP5-AS1 and miR-186-5p as well as miR-186-5p and KIF14 3'-UTR.Com-pared with the NC group and shCtrl group,the shOIP5-AS1 group showed downregulated KIF14 mRNA rela-tive expression(0.41±0.09,P<0.05)and KIF14 protein expression(0.20±0.02,P<0.05).Conversely,the shOIP5-AS1+miR-186-5p inhibitor group exhibited increased KIF14 mRNA relative expression and KIF14 protein expression(0.83±0.12 and 0.62±0.04,respectively)compared to the shOIP5-AS1+miR-NC group.RNA-binding protein immunoprecipitation results also showed that,compared with the control(IgG),the Ago2 antibody could enrich OIP5-AS1 and miR-186-5p.Compared with the shOIP5-AS1+miR-NC group,the shOIP5-AS1+miR-186-5p inhibitor group had significantly increased cell viability and colo-ny formation ability(180.0±11.36 vs 136.0±14.53,P<0.05).In rescue experiments,compared with the shOIP5-AS1+miR-186-5p inhibitor+siNC group,the shOIP5-AS1+miR-186-5p inhibitor+siKIF14 group showed significantly decreased cell viability and colony formation ability(139.33±8.96 vs183.03±18.0,P<0.05).Conclusion:The expression level of OIP5-AS1 is significantly upregulated in SK-N-SH cells and acts as a competing endogenous RNA(ceRNA)to competitively inhibit miR-186-5p,thereby upregulating KIF14 expression and promoting NB progression.

NeuroblastomaLncRNAOpa-interacting protein 5 antisense RNA 1Kinesin family member 14

安艳晓、焦晗亮、祁艳卫、仲智勇

展开 >

河北省儿童医院普外二科,河北 石家庄 050000

神经母细胞瘤 长链非编码RNA Opa相互作用蛋白5反义RNA1 驱动蛋白分子14

河北卫生健康委员会科研计划项目

20240636

2024

河北医学
河北省医学会

河北医学

CSTPCD
影响因子:1.915
ISSN:1006-6233
年,卷(期):2024.30(8)